SI-544(SI-544) - 药物靶点：Kv1.3_在研适应症：银屑病关节炎，寻常性银屑病，1型糖尿病_专利_临床

概要

基本信息

药物类型

合成多肽

别名

SI 544、SI-544

靶点

Kv1.3

作用方式

阻滞剂

作用机制

Kv1.3阻滞剂(电压门控性钾通道蛋白亚型Kv1.3阻滞剂)

治疗领域

免疫系统疾病感染皮肤和肌肉骨骼疾病+ [4]

在研适应症

银屑病关节炎寻常性银屑病1型糖尿病+ [5]

非在研适应症

皮肤T细胞淋巴瘤特应性皮炎

原研机构

selectION, Inc.

在研机构

selectION, Inc.

非在研机构-

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 SI-544 相关的临床试验

NCT06191042

/ Completed临床1期

A Multicenter, Phase 1b, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

The main objective of this study is to investigate the safety and tolerability of si-544.
Other objectives are to study the metabolism of si-544 in the body and to assess the effects of si-544 on cells of the body's immune system (immune cells) that have been chronically activated by the disease. Likewise, the effect of si-544 on inflammatory responses in the body triggered by the disease and other disease symptoms will be investigated.

开始日期2024-01-22

申办/合作机构

selectION, Inc.

[+1]

NCT05383378

/ Completed临床1期

A Multi-center, Phase 1b, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis

This is a multi-center, Phase 1b, double-blind, placebo-controlled, SAD and MAD, first-in-human study in subjects with mild to severe AD receiving si-544. The study consists of 2 parts, an SAD and an MAD part. In both parts, subjects will be treated in cohorts and will be randomized within each cohort to treatment with si-544 or placebo. Initially, 2 sentinel subjects will be treated (randomized to placebo or si-544) in each cohort.

开始日期2022-08-30

申办/合作机构

selectION, Inc.

[+1]

100 项与 SI-544 相关的临床结果

登录后查看更多信息

100 项与 SI-544 相关的转化医学

登录后查看更多信息

100 项与 SI-544 相关的专利（医药）

登录后查看更多信息

9

项与 SI-544 相关的新闻（医药）

2026-05-12

·selectiontherapeutics.com

Meet selectION, Inc. at the BIO International Convention in San Diego, CA, on June 22nd-25th, 2026

SAN DIEGO, May 12, 2026 – Meet selectION’s management team for an update on si-544, selectION’s best-in-class Kv1.3 ion channel blocker in development as a disease-modifying treatment for T cell-mediated autoimmune diseases. selectION recently completed Phase 1b clinical trials in patients with atopic dermatitis and psoriasis, demonstrating excellent safety, tolerability, and early efficacy signals. Further details regarding the Company’s clinical progress and planned Phase 2 development strategy will be discussed during partnering sessions.

临床1期临床2期

2025-12-12

·selectiontherapeutics.com

Meet selectION, Inc. at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 12th-15th, 2026

SAN DIEGO, Dec 12, 2025 – Meet selectION’s management team for an update on selectION’s best-in-class Kv1.3 ion channel blocker, si-544, for the disease modifying treatment of T cell-mediated autoimmunity. selectION successfully completed Phase 1b clinical trials in atopic dermatitis and psoriasis patients, demonstrating excellent safety, tolerability and early efficacy signals. Currently selectION is planning subsequent Phase 2 studies.

临床1期临床2期

2025-05-26

·selectiontherapeutics.com

Meet selectION, Inc. at BIO International Convention in Boston,MA, on June 16th-19th, 2025

SAN DIEGO, May 26, 2025 – Meet selectION’s management team for an update on selectION’s best-in-class Kv1.3 ion channel blocker for the treatment of T-cell mediated autoimmunity while maintaining the patients’ full immunocompetence. selectION successfully completed its first-in-human study with si-544 in atopic dermatitis patients, demonstrating excellent safety, tolerability and early efficacy signals. The currently ongoing Phase1b study in psoriasis patients is expected to be completed in Q3 2025, and is designed to evaluate efficacy at high dose level in preparation of subsequent Phase 2 studies.

100 项与 SI-544 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
银屑病关节炎	临床1期	德国	selectION, Inc.	2024-01-22
寻常性银屑病	临床1期	德国	selectION, Inc.	2024-01-22
特应性皮炎	临床1期	德国	selectION, Inc.	2022-08-30
1型糖尿病	临床前	美国	selectION, Inc.	2026-05-01
化脓性汗腺炎	临床前	美国	selectION, Inc.	2026-05-01
炎症性肠病	临床前	美国	selectION, Inc.	2026-05-01
斑秃	临床前	美国	selectION, Inc.	2025-12-01
非节段型白癜风	临床前	美国	selectION, Inc.	2025-12-01
血管炎	临床前	美国	selectION, Inc.	2025-12-01
皮肤T细胞淋巴瘤	临床前	德国	selectION, Inc.	2025-09-01